You are here: Industry Insights > M&A

News List

Pharmaceutical International Cooperation Under the New Drug Policies in China By ChatGPT ChatGPT/PharmaSources
September 11, 2023
The business environment for pharmaceutical companies in China is generally favorable. China has a large population and a growing middle class, which creates a significant demand for healthcare and pharmaceutical products.
What’s been happening in pharma? - Updates on M&A, Regulatory approvals and collaborations Sarah Harding
June 29, 2020
Key updates in June are summarized here, along with some of the latest industry announcements on new partnerships, M&As and regulatory approvals.
What’s been happening in pharma? - Updates on COVID pandemic Sarah Harding
June 29, 2020
Pharma news in the second half of June continues to be dominated by the COVID pandemic.
CPhI Monthly Podcast: M&A strategies in the CDMO sector cphi-online
June 28, 2021
This month we discuss what is driving M&A strategies in the pharma space, paying particular attention to how investors regard the potential for the growing but fragmented CDMO sector
Federal Trade Commission forms multilateral working group on pharma mergers pharmaceutical-technology
March 18, 2021
The US Federal Trade Commission (FTC) has launched a multilateral working group with domestic and international partners to reassess their approach to analysing the impacts of mergers and acquisitions (M&A) in the pharmaceutical industry.
TA Associates acquires stake in OmniActive Health Technologies expresspharma
January 12, 2021
The company has R&D and manufacturing operations in Pune, Hosur and Thane in India; and sales and distribution operations in the US, Europe, India, Asia, Australia and Latin America.
Value of pharma’s M&A deals remain high, despite COVID-19 europeanpharmaceuticalreview
January 11, 2021
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.
M&As in bio/pharma industry high despite COVID-19: GlobalData expresspharma
December 28, 2020
Down only 13 per cent compared with last year, with a total deal value of $228 billion compared with $262 billion in 2020, and almost twice the 2017 total deal value of $126 billion.
Pharma M&A activity up 17 percent year-on-year in H1 of 2020 europeanpharmaceuticalreview
November 06, 2020
A new report has highlighted that despite the pandemic, pharma M&A activity rose but deal value fell in the first half of 2020.
10 Predictions on How COVID-19 Will Impact Middle Market M&A prnewswire
June 15, 2020
The coronavirus outbreak has impacted just about every aspect of daily life on a global scale, and middle market M&A is no exception.

Previous page 1 2 3 4 5 6 Next page